ZD0473 treatment in lung cancer: An overview of the clinical trial results

J. Treat, J. Schiller, E. Quoix, A. Mauer, M. Edelman, M. Modiano, P. Bonomi, R. Ramlau, E. Lemarie

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Three open-label, non-comparative, multicentre Phase II trials have examined the efficacy and tolerability of ZD0473 as first-and second-line therapy in non-small-cell lung cancer (NSCLC) patients and second-line therapy in small-cell lung cancer (SCLC) patients. Patients with second-line NSCLC or SCLC were evaluated as either platinum-sensitive or -resistant, based upon their time to relapse/progression after platinum-based therapy. First-line NSCLC patients (n = 18) received a total of 60 treatment cycles (median number per patient 2.5) whilst second-line NSCLC (n = 50) and SCLC (n = 48) patients both received a total of 127 treatment cycles (median number per patient 2.0). Grade 3/4 anaemia, neutropenia and thrombocytopenia was observed in: 38.8%, 22.2% and 27.7% of first-line NSCLC patients; 12.0%, 24.0% and 50% of second-line NSCLC patients; and 10.4%, 25.0% and 47.9% of second-line SCLC patients, respectively. The most common grade 3/4 non-haematological toxicities in all three trials were lethargy and dyspnoea. No clinically significant oto-, nephro- or neurotoxicity was observed. The first-line treatment of NSCLC produced an overall response rate (OR) of 6.3%. No OR was seen after second-line treatment of NSCLC, while ORs of 15.4% and 8.3% were seen in the platinum-resistant and -sensitive second-line SCLC patients, respectively.

Original languageEnglish (US)
Pages (from-to)S13-S18
JournalEuropean Journal of Cancer
Issue numberSUPPL. 8
StatePublished - 2002


  • Lung cancer
  • Platinum-resistant
  • Platinum-sensitive
  • SCLC
  • ZD0473

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'ZD0473 treatment in lung cancer: An overview of the clinical trial results'. Together they form a unique fingerprint.

Cite this